Robert g aslanian (15 Ergebnisse)

Zustand: New. This is a Brand-new US Edition. This Item may be shipped from US or any other country as we have multiple locations worldwide.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Zustand: New. pp. 472.

Hardcover. Zustand: New.

HRD. Zustand: New. New Book. Shipped from UK. Established seller since 2000.

Zustand: New. In English.

Gebunden. Zustand: New. Xianhai Huang, PhD, is a Principal Scientist at Merck Research Laboratories. Dr. Huang is the inventor or co-inventor on more than forty patents and patent applications. As a mentor in the Schering-Plough chemistry postdoctoral program, Dr. Huang and his gr.

Hardcover. Zustand: Brand New. 1st edition. 472 pages. 10.10x7.10x1.20 inches. In Stock.

Zustand: New. 2012. 1st Edition. Hardcover. Using case studies of successful drug discoveries and launches, this book helps master the necessary knowledge of the drug discovery process. It includes pharmacology, drug metabolism, biology, drug development, and clinical studies. Editor(s): Huang, Xianhai; Aslanian, Robert G. Num Pages: 472 pages, Illustrations. BIC Classification: MMG; TDCW. Category: (P) Professional & Vocational. Dimension: 261 x 187 x 30. Weight in Grams: 1018. . . . . . Books ship from the US and Ireland. …

Zustand: New. Xianhai Huang, PhD, Executive Director and Head of Discovery Chemistry at InventisBio Co., Ltd.Robert G. Aslanian, PhD, Associate Professor of Chemistry and Chair of the Department at New Jersey City University.Wayne H. Tang, PhD, Executive Director and co-.

Zustand: New. In English.

Buch. Zustand: Neu. Neuware - Learn why some drug discovery and development efforts succeed . . . and others failWritten by international experts in drug discovery and development, this book sets forth carefully researched and analyzed case studies of both successful and failed drug discovery and development efforts, enabling medicinal chemists and pharmaceutical scientists to learn from actual examples. Each case study focuses on a particular drug and therapeutic target, guiding readers through the drug discovery and development process, including drug design rationale, structure-activity relationships, pharmacology, drug metabolism, biology, and clinical studies.Case Studies in Modern Drug Discovery and Development begins with an introductory chapter that puts into perspective the underlying issues facing the pharmaceutical industry and provides insight into future research opportunities. Next, there are fourteen detailed case studies, examining:All phases of drug discovery and development from initial idea to commercializationSome of today's most important and life-saving medicationsDrugs designed for different therapeutic areas such as cardiovascular disease, infection, inflammation, cancer, metabolic syndrome, and allergiesExamples of prodrugs and inhaled drugsReasons why certain drugs failed to advance to market despite major research investmentsEach chapter ends with a list of references leading to the primary literature. There are also plenty of tables and illustrations to help readers fully understand key concepts, processes, and technologies.Improving the success rate of the drug discovery and development process is paramount to the pharmaceutical industry. With this book as their guide, readers can learn from both successful and unsuccessful efforts in order to apply tested and proven science and technologies that increase the probability of success for new drug discovery and development projects.…

Hardcover. Zustand: Brand New. 1st edition. 459 pages. 10.50x7.50x1.25 inches. In Stock.

Buch. Zustand: Neu. Neuware - CONTEMPORARY ACCOUNTS IN DRUG DISCOVERY AND DEVELOPMENTA useful guide for medicinal chemists and pharmaceutical scientistsDrug discovery is a lengthy and complex process that typically involves identifying an unmet medical need, determining a biological target, chemical library screening to identify a lead, chemical optimization, preclinical studies and clinical trials. This process often takes many years to complete, and relies on practitioners' knowledge of chemistry and biology, but also--and perhaps more importantly--on experience. Improving the success rate in discovery and development through a thorough knowledge of drug discovery principles and advances in technology is critical for advancement in the field.Contemporary Accounts in Drug Discovery and Development provides drug discovery scientists with the knowledge they need to quickly gain mastery of the drug discovery process. A thorough accounting is given for each drug covered within the book, as the authors provide pharmacology, drug metabolism, biology, drug development, and clinical studies for every case, with modern drug discovery principles and technologies incorporated throughout.Contemporary Accounts in Drug Discovery and Development readers will also find\* Case histories used as an engaging way of learning about the drug discovery/development process\* Detailed biological rational and background information, drug design principles, SAR development, ADMET considerations, and clinical studies\* The full history of individual marketed small molecule drugs\* Coverage of drug candidates that have passed Phase I clinical trials with different modalities, such as antibody drug conjugates (ADC), proteolysis-targeting chimera (PROTAC), and peptide drugs\* The application of new technologies in drug discovery such as DNA-encoded libraries (DEL), positron emission tomography (PET), and physics-based computational modeling employing free energy perturbation (FEP)Contemporary Accounts in Drug Discovery and Development is a helpful tool for medicinal chemists, organic chemists, pharmacologists, and other scientists in drug research and process development. It may be considered essential reading for graduate courses in drug discovery, medicinal chemistry, drug synthesis, pharmaceutical science, and pharmacology. It is also a useful resource for pharmaceutical industry labs, as well as for libraries.…

Zustand: New. 2022. 1st Edition. Hardcover. . . . . . Books ship from the US and Ireland.